凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
梅花生物(600873)公告正文

梅花集团:2013年第一季度报告

公告日期 2013-04-25
股票简称:梅花生物 股票代码:600873
梅花生物科技集团股份有限公司
           600873
    2013 年第一季度报告
    600873                             梅花生物科技集团股份有限公司 2013 年第一季度报告
                               目录§1 重要提示 ....................................................... 2§2 公司基本情况 ................................................... 3§3 重要事项 ....................................................... 5§4 附录 ........................................................... 8
    600873                                  梅花生物科技集团股份有限公司 2013 年第一季度报告§1 重要提示1.1 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。1.2 公司全体董事出席董事会会议。1.3 公司第一季度财务报告未经审计。1.4
    公司负责人姓名                            孟庆山
    主管会计工作负责人姓名                    李勇刚
    会计机构负责人(会计主管人员)姓名        陶忠公司负责人孟庆山、主管会计工作负责人李勇刚及会计机构负责人(会计主管人员)陶忠声明:保证本季度报告中财务报告的真实、完整。
    600873                                        梅花生物科技集团股份有限公司 2013 年第一季度报告§2 公司基本情况2.1 主要会计数据及财务指标
                                                                                       币种:人民币
                                                                                   本报告期末比上
                                             本报告期末           上年度期末          年度期末增减
                                                                                          (%)
    总资产(元)                                21,000,302,803.04    17,098,314,827.01                22.82
    所有者权益(或股东权益)(元)               8,079,822,572.67     5,481,286,521.83                47.41
    归属于上市公司股东的每股净资产(元/股)                 2.60                2.02                28.71
                                                                                   比上年同期增减
                                                    年初至报告期期末
                                                                                          (%)
    经营活动产生的现金流量净额(元)                                   -306,710,683.76            -220.48
    每股经营活动产生的现金流量净额(元/股)                                    -0.10            -211.11
                                                                                   本报告期比上年
                                               报告期          年初至报告期期末
                                                                                      同期增减(%)
    归属于上市公司股东的净利润(元)               145,588,542.14       145,588,542.14                -3.32
    基本每股收益(元/股)                                   0.05                0.05             -16.67扣除非经常性损益后的基本每股收益(元/
                                                        0.04                0.04                     0股)
    稀释每股收益(元/股)                                   0.05                0.05             -16.67
                                                                                   减少 0.27 个百分
    加权平均净资产收益率(%)                               2.62                2.62
                                                                                                  点
    扣除非经常性损益后的加权平均净资产收益                                             减少 0.19 个百分
                                                        2.01                2.01
    率(%)                                                                                           点扣除非经常性损益项目和金额:
                                                                           单位:元 币种:人民币
                            项目                                               金额
    非流动资产处置损益                                                                           619.81计入当期损益的政府补助,但与公司正常经营业务密切相关,符合国
                                                                                      39,192,463.44家政策规定、按照一定标准定额或定量持续享受的政府补助除外除同公司正常经营业务相关的有效套期保值业务外,持有交易性金融
    资产、交易性金融负债产生的公允价值变动损益,以及处置交易性金                             526,002.76融资产、交易性金融负债和可供出售金融资产取得的投资收益
    除上述各项之外的其他营业外收入和支出                                                     179,142.21
    所得税影响额                                                                          -5,856,993.42
                            合计                                                      34,041,234.80
    600873                                          梅花生物科技集团股份有限公司 2013 年第一季度报告2.2 报告期末股东总人数及前十名无限售条件股东持股情况表
                                                                                        单位:股
                报告期末股东总数(户)                                     68,705
                                 前十名无限售条件流通股股东持股情况
                                        期末持有无限售条
          股东名称(全称)                件流通股的数量                    种类
               胡继军                      369,394,122          人民币普通股
      香港鼎晖生物科技有限公司             335,625,120          人民币普通股
    新天域生化科技投资有限公司            261,106,616          人民币普通股
               李宝骏                       58,020,019          人民币普通股
               梁宇擘                       53,668,518          人民币普通股
               王加琪                       19,823,507          人民币普通股
               郭振群                       19,340,006          人民币普通股
               潘耀冬                       18,856,506          人民币普通股
               王友山                       18,131,256          人民币普通股
               高红臣                       12,812,754          人民币普通股
    600873                                              梅花生物科技集团股份有限公司 2013 年第一季度报告§3 重要事项3.1 公司主要会计报表项目、财务指标大幅度变动的情况及原因√适用 □不适用1)资产负债表项目:
                                                                                                单位:万元
                                                                  增减幅度
         项目       期末余额          年初余额       增减额                                变动原因
                                                                    (%)
       货币资金      358,792.04        86,360.74    272,431.30      315.46     收到非公开发行款项
       预付账款      115,642.34        81,903.69     33,738.65         41.19   预付代收代储玉米款项
                                                                               应收出口退税和汇丰银行保理
    其他应收款          6,974.23         3,100.82      3,873.41      124.92
                                                                               业务增加
         存货        151,970.52        94,475.72     57,494.81         60.86   原材料和库存商品增加
       工程物资        4,598.96         9,902.26     -5,303.29       -53.56    新疆梅花氨基酸工程领用减少
                                                                               增加西藏中行、兴业银行、胜芳
       短期借款      508,987.19       297,683.93    211,303.26         70.98
                                                                               农行和农发行借款
       应付票据                  -     16,550.00    -16,550.00         -100    票据到期解付
       应交税费      -15,562.21       -26,002.08     10,439.87       -40.15    应交增值税和企业所得税增加一年内到期的非
                       8,000.00        60,000.00    -52,000.00       -86.67    偿还厦门信托和招行借款
    流动负债
       资本公积      224,048.59        18,752.84    205,295.75     1,094.74    非公开发行资本溢价增加2)利润表项目
                                                                                               单位:万元
                                                                 增减幅度
    项目              本期金额           上期金额       增减额       (%)         变动原因
    营业税金及附加       714.9             79.39        635.51        800.48             本期流转税增加
       销售费用     12,103.43         6,870.93       5,232.50      76.15           运费随销售增加而增加
       财务费用      5,099.64         8,670.24      -3,570.61      -41.18                 利息支出减少
    营业外支出         51.12            220.48        -169.36       -76.81         非流动资产处置损失减少3)现金流量表项目
                                                                                               单位:万元
      项目        本期金额            上期金额           增减额            增减幅度(%) 变动原因
    经营活动产生的                                                                            预付代收代储 玉米
    现金流量净额        -30,671.07          25,457.72         -56,128.79              -220.48 款及材料款增加
    筹资活动产生的                                                                            吸收投资和取 得借
    现金流量净额        348,410.44         -35,600.17         384,010.61           -1,078.68  款增加3.2 重大事项进展情况及其影响和解决方案的分析说明
    600873                                        梅花生物科技集团股份有限公司 2013 年第一季度报告√适用 □不适用
    2012 年 9 月 27 日,公司收到中国证监会出具的《关于核准梅花生物科技集团股份有限公司非公开发行股票的批复》(证监许可[2012]1262 号),本次发行获得了中国证监会的核准。公司于 2013 年 3 月 22 日以非公开发行股票的方式向特定投资者发行了 39,999 万股人民币普通股(A 股)。2013 年 3 月 26 日,主承销商将上述认购款项扣除承销保荐费后的余额划转至公司指定的本次募集资金专户内。2013 年 3 月 26 日,大华会计师事务所出具了《验资报告》(大华验字[2013]000071 号)。根据验资报告,截至 2013 年 3 月 26 日,本次发行募集资金总额2,507,937,300.00 元,扣除发行费用 54,989,791.30 元,募集资金净额 2,452,947,508.70 元。本次发行的 A 股股份已于 2013 年 3 月 29 日在中国证券登记结算有限责任公司上海分公司完成股份登记托管及股份限售手续。本次向特定投资者发行的股份自发行结束之日起十二个月内不得转让,该部分新增股份预计可上市交易的时间为 2014 年 3 月 30 日,如遇法定节假日或休息日,则顺延至其后的第一个交易日。(具体内容详见上海证券交易所公司 2013 年 4 月 3 日出具的公告《梅花生物科技集团股份有限公司非公开发行股票发行结果暨股本变动公告》)
    本次发行完成后,公司股本将相应增加,公司将按照发行的实际情况对《公司章程》中与股本相关的条款进行修改,并办理工商变更登记。
    非公开发行股票发行完毕后,公司将按照相关规定和程序增资募投项目实施主体新疆梅花,予以置换已预先投入募集资金投资项目的自筹资金 2,452,947,508.70 元。该事项已经公司第六届董事会第二十五次会议审议通过。详见 2013 年 4 月 11 日发布的《梅花生物科技集团股份有限公司关于以募集资金置换预先已投入募投项目自筹资金的公告》(2013-005)和《梅花生物科技集团股份有限公司关于向全资子公司新疆梅花氨基酸有限责任公司增资的公告》(2013-006)。目前,增资事项已经完成,新疆梅花于 2013 年 4 月 16 日在工商登记部门换领了新的营业执照,增资完成后,新疆梅花注册资本为 25 亿元。3.3 公司、股东及实际控制人承诺事项履行情况√适用 □不适用
                                                                               是否有   是否及
            承诺类                                                             履行期   时严格
    承诺背景     型         承诺方                      承诺内容                    限       履行
                                      孟庆山及其一致行动人承诺:重组实
                                      施完毕后的三年归属母公司净利润不
                                      低于北京天健兴业资产评估有限公司
            盈利预                    出具的编号为天兴评报字(2009)第
                     孟庆山及其一致
            测及补                    117 号《资产评估报告书》上的盈利预         是       是
                     行动人
            偿                        测数,即 2010 年归属母公司净利润
    与重大资                              67,311.14 万元,2011 年归属母公司净
    产重组相                              利润 61,890.37 万元,2012 年归属母公
    关的承诺                              司净利润 58,847.22 万元。
                                      孟庆山及其一致行动人承诺:通过本
                                      次交易取得的股份自登记至其账户之
            股份限   孟庆山及其一致   日 起 三十 六个月 内 不上 市交易 或 转
                                                                                 是       是
            售       行动人           让。
    600873                                        梅花生物科技集团股份有限公司 2013 年第一季度报告
                                      在孟庆山先生及一致行动人作为上市
                                      公 司 控股 股东或 实 际控 制人之 期 限
                                      内,将采取有效措施,并促使孟庆山
            解决同   孟庆山及其一致   先生或孟庆山先生及一致行动人下属
                                                                                否       是
            业竞争   行动人           控股子公司采取有效措施,不会从事
                                      或参与任何可能对上市公司或其控股
                                      子公司目前主要从事的业务构成竞争
                                      的业务。
                                      在重组完成后,孟庆山先生及一致行
                                      动人将尽量避免与上市公司的关联交
                                      易,若有不可避免的关联交易,孟庆
                                      山先生及一致行动人与上市公司将依
            解决关   孟庆山及其一致
                                      法签订协议,履行合法程序,并将按          否       是
            联交易   行动人
                                      照有关法律、法规、《公司章程》等
                                      有关规定履行信息披露义务和办理有
                                      关报批事宜。保证不通过关联交易损
                                      害上市公司及其他股东的合法权益。3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生大幅度变动的警示及原因说明□适用 √不适用3.5 报告期内现金分红政策的执行情况
    2012 年 4 月 16 日,公司召开第六届董事会第二十六次会议,会上审议通过了关于《2012年度利润分配方案(预案)》的议案,公司拟以现有总股本 3,108,226,603 股为基数,向全体股东每 10 股分配现金红利 1.00 元(含税),预计分配利润 310,822,660.30 元。该议案尚需提交 2012年度股东大会审议。
                                                                  梅花生物科技集团股份有限公司
                                                                               __________________
                                                                                法定代表人:孟庆山
                                                                                 2013 年 4 月 24 日§4 附录4.1
                                 合并资产负债表
                                2013 年 3 月 31 日编制单位: 梅花生物科技集团股份有限公司
                                        单位:元 币种:人民币 审计类型:未经审计
                       项目                   期末余额            年初余额流动资产:
      货币资金                                3,587,920,394.32      863,607,411.88
      结算备付金
      拆出资金
      交易性金融资产
      应收票据                                  295,221,889.77      353,160,224.69
      应收账款                                  322,992,274.67      296,388,532.90
      预付款项                                1,156,423,409.14      819,036,895.74
      应收保费
      应收分保账款
      应收分保合同准备金
      应收利息
      应收股利
      其他应收款                                 69,742,341.67       31,008,199.29
      买入返售金融资产
      存货                                    1,519,705,243.80      944,757,172.43
      一年内到期的非流动资产
      其他流动资产
       流动资产合计                           6,952,005,553.37    3,307,958,436.93非流动资产:
      发放委托贷款及垫款
      可供出售金融资产
      持有至到期投资
      长期应收款
      长期股权投资                              151,601,465.22      151,863,027.17
      投资性房地产
      固定资产                                6,997,548,802.48    5,773,295,917.22
      在建工程                                5,623,720,346.74    6,514,739,811.73
      工程物资                                   45,989,626.65       99,022,563.68
      固定资产清理
      生产性生物资产
      油气资产
      无形资产                                  800,478,620.57      805,775,992.57
      开发支出
      商誉                                       11,788,911.79       11,788,911.79
      长期待摊费用
    递延所得税资产                  10,633,346.68       10,633,346.68
    其他非流动资产                 406,536,129.54      423,236,819.24
    非流动资产合计             14,048,297,249.67   13,790,356,390.08
         资产总计               21,000,302,803.04   17,098,314,827.01流动负债:
    短期借款                      5,089,871,892.28    2,976,839,312.50
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    交易性金融负债
    应付票据                                           165,500,000.00
    应付账款                      1,834,562,112.52    1,976,865,223.02
    预收款项                       252,774,703.46      250,134,053.69
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                    40,379,400.04       31,093,084.98
    应交税费                       -155,622,106.63     -260,020,834.67
    应付利息                       126,554,757.98      160,468,447.14
    应付股利
    其他应付款                     408,348,382.12      380,588,966.48
    应付分保账款
    保险合同准备金
    代理买卖证券款
    代理承销证券款
    一年内到期的非流动负债          80,000,000.00      600,000,000.00
    其他流动负债                  1,995,968,333.89    1,995,968,333.89
    流动负债合计                9,672,837,475.66    8,277,436,587.03非流动负债:
    长期借款                      1,300,000,000.00    1,400,000,000.00
    应付债券                      1,893,435,664.59    1,885,035,664.59
    长期应付款
    专项应付款
    预计负债
    递延所得税负债
    其他非流动负债                  54,207,090.12       54,556,053.56
    非流动负债合计              3,247,642,754.71    3,339,591,718.15
         负债合计                                   12,920,480,230.37      11,617,028,305.18所有者权益(或股东权益):
    实收资本(或股本)                              3,108,226,603.00       2,708,236,603.00
    资本公积                                        2,240,485,918.58        187,528,409.88
    减:库存股
    专项储备
    盈余公积                                         158,068,747.24         158,068,747.24
    一般风险准备
    未分配利润                                      2,573,041,303.85       2,427,452,761.71
    外币报表折算差额
    归属于母公司所有者权益合计                      8,079,822,572.67       5,481,286,521.83
    少数股东权益
            所有者权益合计                           8,079,822,572.67       5,481,286,521.83
         负债和所有者权益总计                       21,000,302,803.04      17,098,314,827.01
    公司法定代表人: 孟庆山          主管会计工作负责人:李勇刚        会计机构负责人:陶忠
                                母公司资产负债表
                                2013 年 3 月 31 日编制单位: 梅花生物科技集团股份有限公司
                                              单位:元 币种:人民币 审计类型:未经审计
                      项目                          期末余额               年初余额流动资产:
    货币资金                                        2,486,399,304.87        177,024,125.08
    交易性金融资产
    应收票据                                               499,750.00          1,110,000.00
    应收账款                                          52,444,617.26          51,138,661.71
    预付款项                                            5,815,829.25           4,793,310.13
    应收利息
    应收股利                                         500,000,000.00         500,000,000.00
    其他应收款                                      9,233,842,318.96       8,530,246,117.81
    存货                                              15,302,763.30          28,405,644.95
    一年内到期的非流动资产
    其他流动资产
       流动资产合计                                 12,294,304,583.64       9,292,717,859.68非流动资产:
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资                                    2,934,601,465.22       2,934,863,027.17
    投资性房地产
    固定资产                                         709,060,035.77         730,588,575.81
    在建工程                         39,165,866.57       39,164,865.58
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                         98,625,197.72       99,725,962.72
    开发支出
    商誉
    长期待摊费用
    递延所得税资产                         8,774.68            8,774.68
    其他非流动资产
      非流动资产合计               3,781,461,339.96    3,804,351,205.96
        资产总计                  16,075,765,923.60   13,097,069,065.64流动负债:
    短期借款                       2,260,500,000.00    1,160,500,000.00
    交易性金融负债
    应付票据
    应付账款                         57,235,159.12       59,923,703.56
    预收款项                           2,062,405.31        1,319,830.93
    应付职工薪酬                       5,327,049.83        5,690,691.50
    应交税费                          -3,148,943.10      22,659,276.08
    应付利息                        123,059,179.17      155,180,176.95
    应付股利
    其他应付款                     2,362,457,783.88    2,241,065,160.17
    一年内到期的非流动负债                              500,000,000.00
    其他流动负债                   1,995,968,333.89    1,995,968,333.89
      流动负债合计                 6,803,460,968.10    6,142,307,173.08非流动负债:
    长期借款                       1,300,000,000.00    1,400,000,000.00
    应付债券                       1,893,435,664.59    1,885,035,664.59
    长期应付款
    专项应付款
    预计负债
    递延所得税负债
    其他非流动负债
      非流动负债合计               3,193,435,664.59    3,285,035,664.59
        负债合计                   9,996,896,632.69    9,427,342,837.67所有者权益(或股东权益):
    实收资本(或股本)             3,108,226,603.00    2,708,236,603.00
    资本公积                       2,208,701,622.94     155,744,114.24
    减:库存股
    专项储备
      盈余公积                                          158,068,747.24        158,068,747.24
      一般风险准备
      未分配利润                                        603,872,317.73        647,676,763.49
    所有者权益(或股东权益)合计                          6,078,869,290.91      3,669,726,227.97
          负债和所有者权益(或股东权益)总计          16,075,765,923.60     13,097,069,065.64
    公司法定代表人: 孟庆山         主管会计工作负责人:李勇刚         会计机构负责人:陶忠4.2
                                    合并利润表
                                  2013 年 1—3 月编制单位: 梅花生物科技集团股份有限公司
                                         单位:元 币种:人民币 审计类型:未经审计
                       项目                           本期金额              上期金额
    一、营业总收入                                        1,866,927,387.17      1,809,875,061.07
      其中:营业收入                                   1,866,927,387.17      1,809,875,061.07
            利息收入
            已赚保费
            手续费及佣金收入
    二、营业总成本                                        1,724,695,548.57      1,653,045,049.30
      其中:营业成本                                   1,458,193,454.18      1,395,991,382.60
            利息支出
            手续费及佣金支出
            退保金
            赔付支出净额
            提取保险合同准备金净额
            保单红利支出
            分保费用
            营业税金及附加                                 7,149,007.64           793,911.10
            销售费用                                    121,034,292.71         68,709,250.34
            管理费用                                     87,322,441.30        100,848,094.56
            财务费用                                     50,996,352.74         86,702,410.70
            资产减值损失
      加:公允价值变动收益(损失以“-”号填列)
          投资收益(损失以“-”号填列)                    264,440.81            740,266.54
            其中:对联营企业和合营企业的投资收
                                                            -261,561.95           500,406.33益
          汇兑收益(损失以“-”号填列)
    三、营业利润(亏损以“-”号填列)                     142,496,279.41        157,570,278.31
      加:营业外收入                                     39,883,472.76         44,151,978.52
      减:营业外支出                                        511,247.30           2,204,802.50
        其中:非流动资产处置损失                                 916.73          2,090,727.47
    四、利润总额(亏损总额以“-”号填列)                 181,868,504.87        199,517,454.33
      减:所得税费用                                    36,279,962.73           48,923,425.74
    五、净利润(净亏损以“-”号填列)                    145,588,542.14          150,594,028.59
      归属于母公司所有者的净利润                       145,588,542.14          150,594,028.59
      少数股东损益六、每股收益:
      (一)基本每股收益                                           0.05                   0.06
      (二)稀释每股收益                                           0.05                   0.06七、其他综合收益
    八、综合收益总额                                      145,588,542.14          150,594,028.59
      归属于母公司所有者的综合收益总额                 145,588,542.14          150,594,028.59
      归属于少数股东的综合收益总额
    公司法定代表人: 孟庆山             主管会计工作负责人:李勇刚        会计机构负责人:陶忠
                                   母公司利润表
                                  2013 年 1—3 月编制单位: 梅花生物科技集团股份有限公司
                                         单位:元 币种:人民币 审计类型:未经审计
                       项目                           本期金额               上期金额
    一、营业收入                                           59,104,610.02          188,065,032.99
      减:营业成本                                      65,216,550.76          195,745,963.66
          营业税金及附加                                   175,223.94             661,012.95
          销售费用                                         351,883.20             128,347.32
          管理费用                                      36,198,527.12           31,775,474.70
          财务费用                                         840,525.10           32,766,162.73
          资产减值损失
      加:公允价值变动收益(损失以“-”号填列)
          投资收益(损失以“-”号填列)                    -74,038.65            509,097.99
            其中:对联营企业和合营企业的投资收
                                                          -261,561.95             500,406.33益
    二、营业利润(亏损以“-”号填列)                     -43,752,138.75         -72,502,830.38
      加:营业外收入                                        23,166.59               50,308.06
      减:营业外支出                                        75,473.60             470,071.78
        其中:非流动资产处置损失                                 473.60           380,841.78
    三、利润总额(亏损总额以“-”号填列)                 -43,804,445.76         -72,922,594.10
      减:所得税费用                                                               162,611.38
    四、净利润(净亏损以“-”号填列)                     -43,804,445.76         -73,085,205.48五、每股收益:
      (一)基本每股收益
      (二)稀释每股收益六、其他综合收益
    七、综合收益总额                                       -43,804,445.76         -73,085,205.48
    公司法定代表人: 孟庆山         主管会计工作负责人:李勇刚             会计机构负责人:陶忠4.3
                                合并现金流量表
                                  2013 年 1—3 月编制单位: 梅花生物科技集团股份有限公司
                                         单位:元 币种:人民币 审计类型:未经审计
                         项目                           本期金额           上期金额一、经营活动产生的现金流量:
      销售商品、提供劳务收到的现金                      1,727,648,290.26   1,695,569,978.79
      客户存款和同业存放款项净增加额
      向中央银行借款净增加额
      向其他金融机构拆入资金净增加额
      收到原保险合同保费取得的现金
      收到再保险业务现金净额
      保户储金及投资款净增加额
      处置交易性金融资产净增加额
      收取利息、手续费及佣金的现金
      拆入资金净增加额
      回购业务资金净增加额
      收到的税费返还
      收到其他与经营活动有关的现金                         42,210,834.66      45,671,438.53
        经营活动现金流入小计                            1,769,859,124.92   1,741,241,417.32
      购买商品、接受劳务支付的现金                      1,819,124,256.66   1,126,717,259.05
      客户贷款及垫款净增加额
      存放中央银行和同业款项净增加额
      支付原保险合同赔付款项的现金
      支付利息、手续费及佣金的现金
      支付保单红利的现金
      支付给职工以及为职工支付的现金                       77,918,060.10     116,011,122.99
      支付的各项税费                                       66,519,798.12     144,662,789.23
      支付其他与经营活动有关的现金                        113,007,693.80      99,273,044.00
        经营活动现金流出小计                            2,076,569,808.68   1,486,664,215.27
          经营活动产生的现金流量净额                     -306,710,683.76     254,577,202.05二、投资活动产生的现金流量:
      收回投资收到的现金
      取得投资收益收到的现金                                 526,002.76         239,860.21
      处置固定资产、无形资产和其他长期资产收回的
                                                                2,000.00        363,412.48现金净额
      处置子公司及其他营业单位收到的现金净额
      收到其他与投资活动有关的现金
        投资活动现金流入小计                                 528,002.76         603,272.69
      购建固定资产、无形资产和其他长期资产支付的
                                                          721,571,186.30     600,301,137.78现金
      投资支付的现金
    质押贷款净增加额
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
    投资活动现金流出小计                              721,571,186.30           600,301,137.78
       投资活动产生的现金流量净额                     -721,043,183.54          -599,697,865.09三、筹资活动产生的现金流量:
    吸收投资收到的现金                                2,457,778,554.00
    其中:子公司吸收少数股东投资收到的现金
    取得借款收到的现金                                3,645,166,626.13           342,659,510.47
    发行债券收到的现金
    收到其他与筹资活动有关的现金                                                 106,417,255.21
    筹资活动现金流入小计                            6,102,945,180.13           449,076,765.68
    偿还债务支付的现金                                2,152,224,255.50           615,588,098.97
    分配股利、利润或偿付利息支付的现金                  182,597,254.83           186,790,368.44
    其中:子公司支付给少数股东的股利、利润
    支付其他与筹资活动有关的现金                        284,019,305.92             2,700,000.00
    筹资活动现金流出小计                            2,618,840,816.25           805,078,467.41
       筹资活动产生的现金流量净额                    3,484,104,363.88          -356,001,701.73
    四、汇率变动对现金及现金等价物的影响                   -11,166,830.06             1,613,630.80
    五、现金及现金等价物净增加额                         2,445,183,666.52          -699,508,733.97
    加:期初现金及现金等价物余额                        580,166,305.18         1,652,684,850.59
    六、期末现金及现金等价物余额                         3,025,349,971.70           953,176,116.62
    公司法定代表人: 孟庆山          主管会计工作负责人:李勇刚          会计机构负责人:陶忠
                                母公司现金流量表
                                  2013 年 1—3 月编制单位: 梅花生物科技集团股份有限公司
                                              单位:元 币种:人民币 审计类型:未经审计
                      项目                          本期金额                上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                      63,391,680.28          246,885,435.06
    收到的税费返还
    收到其他与经营活动有关的现金                     923,535,921.89          858,211,758.61
       经营活动现金流入小计                           986,927,602.17         1,105,097,193.67
    购买商品、接受劳务支付的现金                      56,000,115.44          203,282,380.88
    支付给职工以及为职工支付的现金                    10,610,171.28           22,240,064.58
    支付的各项税费                                      4,661,508.43          13,034,698.03
    支付其他与经营活动有关的现金                     936,595,439.79          887,043,437.43
       经营活动现金流出小计                          1,007,867,234.94        1,125,600,580.92
         经营活动产生的现金流量净额                    -20,939,632.77          -20,503,387.25二、投资活动产生的现金流量:
    收回投资收到的现金
    取得投资收益收到的现金                                 187,523.30               8,691.66
    处置固定资产、无形资产和其他长期资产收回
                                                              2,000.00        23,682,486.38的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金
       投资活动现金流入小计                                 189,523.30        23,691,178.04
    购建固定资产、无形资产和其他长期资产支付
                                                            951,068.51          5,078,336.86的现金
    投资支付的现金
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
       投资活动现金流出小计                                 951,068.51          5,078,336.86
          投资活动产生的现金流量净额                     -761,545.21          18,612,841.18三、筹资活动产生的现金流量:
    吸收投资收到的现金                              2,457,778,554.00
    取得借款收到的现金                              2,100,000,000.00        270,000,000.00
    发行债券收到的现金
    收到其他与筹资活动有关的现金                    1,922,109,666.48        702,697,368.45
       筹资活动现金流入小计                          6,479,888,220.48        972,697,368.45
    偿还债务支付的现金                              1,600,000,000.00        200,000,000.00
    分配股利、利润或偿付利息支付的现金               124,682,317.06         142,808,630.56
    支付其他与筹资活动有关的现金                    2,423,889,990.00       1,306,500,000.00
       筹资活动现金流出小计                          4,148,572,307.06       1,649,308,630.56
          筹资活动产生的现金流量净额                 2,331,315,913.42        -676,611,262.11
    四、汇率变动对现金及现金等价物的影响                            -0.28                 -0.11
    五、现金及现金等价物净增加额                        2,309,614,735.16       -678,501,808.29
    加:期初现金及现金等价物余额                     176,130,498.65         953,363,989.00
    六、期末现金及现金等价物余额                        2,485,745,233.81        274,862,180.71
    公司法定代表人: 孟庆山          主管会计工作负责人:李勇刚        会计机构负责人:陶忠
数据加载中...
prevnext
手机查看股票